Market revenue in 2023 | USD 182.0 million |
Market revenue in 2030 | USD 328.5 million |
Growth rate | 8.8% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.57% in 2024. Horizon Databook has segmented the Spain in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Spain is considered to be a major offshoring & outsourcing country for conducting preclinical & clinical studies, owing to the availability of experienced investigators, established research quality, and a skilled workforce. In addition, approximately 19% of the R&D investment in the country is dedicated to the pharmaceutical industry.
Continuous support from the government has improved the healthcare infrastructure in the country and has accelerated the advancements in R&D. These factors are expected to increase the demand for in vivo CRO services as pharmaceutical companies seek external expertise for their R&D activities. This trend is anticipated to propel market growth during the forecast period.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account